Iran Pharmaceuticals and Healthcare Report Q3 2009

Publication Date	June 2009
Publisher	Business Monitor
Product Type	Report
Pages	72
ISBN Number	1748-1953
Product Code	BMI02574

Buy this product or for assistance call +44 20 7060 7474

PDF £250.00$416 | €280

FAX Order above formats by FAX

Summary

For BMI's Q309 Iran Pharmaceutical and Healthcare Report, we expect a 9.0% compound annual growth rate (CAGR) for the total pharmaceutical market, meaning an increase in total value from US$2.27bn in 2008 to US$3.50bn by 2013. We believe the main drivers for growth will include a growing population, a rise in domestic drug manufacturing, and the greater burden of disease imposed by respiratory illnesses.

Total healthcare spending is expected to rise from US$25.2bn in 2008, to US$41.8bn by 2013, reflecting the increasing demand on medical services.

On the regulatory front, Iran is still failing to attract considerable multinational interest. While the R&D in the country is accelerating, with governmental backing and promotion in boosting the domestic drug sector, we note that patent and intellectual property protection is still a strong deterrent. Although the US Trade Representative (USTR) Special 301 Report has not highlighted Iran, we note that this is due to the lack of international collaboration between Iran and developed countries.

We believe that the potential for Iran's drug market to grow is hindered by its poor regulatory environment, with our Business Environment Rankings for IP protection only scoring a meagre two out of 10, with approvals a marginally higher score of three. Among the Middle East region, Iran's IP environment is poor, with Kuwait attaining five, and Egypt also a two. BMI highlights that although the lack of adequate patent protection is an ongoing issue within the Middle East, Iran's economic isolation will continue to hinder any real development in this arena.

It is highly unlikely that Iran will make any significant positive advances on this front in the medium term. While the drive to promote domestic drug production will establish a stronger domestic pharmaceutical sector, we caution that even without import restrictions the lack of transparent legislation on patent laws will add another layer of difficulties for foreign drugmakers expanding operations within the Middle East.

Content

Executive Summary
SWOT Analysis
Iran Political SWOT
Iran Economic SWOT
Iran Business Environment SWOT
Business Environment Ranking
Limits Of Potential Returns
Risks To Realisation Of Returns
Market Summary
Registration Of Imports
Generic Registration
Intellectual Property (IP) Regime
Intellectual Property Disputes
Counterfeit Medicines
Pricing And Reimbursement
Recent Pricing And Reimbursement Developments
Industry Developments
Epidemiology
HIV/AIDS Situation
Healthcare Sector
Primary Care
Secondary Care
Health Insurance
Regional Developments
International Healthcare Collaboration
Pharmaceutical Industry
Pharmaceutical Industry Recent Developments
Traditional Herbal Remedies
Recent Company Activity
Retail Pharmacies
Research And Development
International Pharmaceutical Collaboration
Industry Forecast Scenario
Overall Drug Market Forecast
Industry Growth Factors
Macroeconomic Growth Factors
Prescription Drug Market Forecast
OTC Drug Market Forecast
Patented Drug Market Forecast
Generic Drug Market Forecast
Medical Device Market Forecast
Import/Export Market Forecast
Other Healthcare Data Forecasts
Key Risks To BMI's Forecast Scenario
Competitive Landscape
Company Profiles
Multinationals
Novartis
Merck & Co
Pfizer
GlaxoSmithKline
Sanofi-Aventis
Indigenous Companies
Darou Pakhsh
Caspian Tamin Pharmaceutical Company*
Pharmieco
Pars Darou
Zahravi
Amin
Sina Darou Pharmaceutical Company
Exir Pharmaceuticals
Country Snapshot: Iran Demographic Data
Section 1: Population
Section 2: Education And Healthcare
Section 3: Labour Market And Spending Power
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Weighting
List of Tables
- Table: Iran Pharmaceuticals And Healthcare Industry SWOT
- Table: Middle East And Africa Pharmaceutical Business Environment Ratings Q309
- Table: Iran HIV/AIDS Prevalence
- Table: Iran - Drug Expenditure Forecasts, 2003-2013
- Table: Iran - Health Expenditure Forecasts, 2003-2013
- Table: Iran - Economic Activity
- Table: Iran - Prescription Drug Market Forecast, 2003-2013 (US$mn unless otherwise stated)
- Table: Iran - OTC Market Data Forecasts, 2003-2013 (US$mn unless otherwise stated)
- Table: Iran - Patented Market Forecasts, 2003-2013
- Table: Iran - Generics Market Forecasts, 2003-2013
- Table: Iran - Medical Device Market Forecast, 2006-2013
- Table: Iran - Pharmaceutical Trade Indicators, 2003-2013 (US$mn)
- Table: Iran - Other Health Indicators, 2003-2013
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Table: Employment Indicators, 1996-2005
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Manufacturing Wages, 2000-2012
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components

Delivery Details

PDF:Immediate delivery

Ask a question about this product

Need help finding the right product?

Product features / use

Level	General Industry Strategies
Data	Detailed Market Forecasts
Profiles	Profiles of Key Companies
Features	Contains SWOT Analysis
Extra Info	Consumer Trends Highlighted